News | News By Subject | News by Disease News By Date | Search News

Narcolepsy News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Novartis AG (NVS) Researchers ID Possible Link Between GlaxoSmithKline (GSK) Flu Vaccine, Narcolepsy     7/6/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Scientists Retract Narcolepsy Study Linked To GlaxoSmithKline (GSK) Flu Vaccine     8/11/2014
Jazz Pharmaceuticals plc (JAZZ) Forges Pact Worth $397 Million For Aerial BioPharma's Sleepiness Drug     1/13/2014
GlaxoSmithKline (GSK) Flu Shot May Raise Adult Narcolepsy Risk     5/23/2013
Concert Pharmaceuticals, Inc., Jazz Pharmaceuticals plc (JAZZ) Strike $120 Million Deal for Narcolepsy     2/22/2013
GlaxoSmithKline (GSK) Vaccine Linked to 800 Children Narcolepsy Cases in EU     1/28/2013
Sleep Tight: GlaxoSmithKline (GSK) Vaccine Not Linked To Narcolepsy     10/19/2012
European Medicines Evaluation Agency Finds No Narcolepsy Link to GlaxoSmithKline (GSK)'s Flu Vaccine     9/24/2010
Alfresa Pharma Corporation And Tanabe Seiyaku Company To Collaborate In Development And Sales Of Narcolepsy Drug Modafinil     4/5/2006
Jazz Pharmaceuticals, Inc. Release: Xyrem(R) Receives FDA Approval For The Treatment Of Excessive Daytime Sleepiness In Patients With Narcolepsy     11/23/2005
Cephalon, Inc. (CEPH) ADHD Drug Takes Step Closer To Approval     10/21/2005
Jazz Pharmaceuticals, Inc. To Buy Orphan Medical, Inc. (ORPH) For About $122.6 Million In Cash     4/19/2005
Cephalon (CEPH) Announces Positive Clinical Trial Results For NUVIGIL(TM)     2/10/2005

News from Around the Web
Sleep Gene Linked To Heart Failure, Stanford University School of Medicine Study     12/2/2015
GlaxoSmithKline (GSK)'s Flu Vaccine Helps Unravel Complex Causes Of Narcolepsy     12/23/2013
Why Flu Vaccine May Cause Narcolepsy, World Health Organization Reveals     2/11/2011
Narcolepsy Drug Fixes FM Sleep Symptoms, University of Texas Medical School Study     4/20/2010
University of California, Los Angeles (UCLA) Researchers Discover Link Between Parkinson's and Narcolepsy     5/14/2007
Narcolepsy Hints At Drug For Insomniacs     2/7/2007
Narcolepsy Drug Eyed For Cocaine Users     4/25/2006
"Memory Pill" For The Forgetful     5/12/2005
Immune System Link To Narcolepsy     12/13/2004
Green Tea Lulls Brain Into Quality Sleep     3/17/2004
Brain Chemical Helps Narcolepsy     3/16/2004
Caffeine, Melatonin May Ease Jet Lag     2/9/2004

Press Releases
Breckenridge Pharmaceutical, Inc. Announces Final ANDA Approval For Armodafinil Tablets (CIV) In 50mg, 150mg And 250 Mg Strengths (Nuvigil)     11/29/2016
Jazz Pharma (JAZZ) Announces That Patient Enrollment Is Complete For The Phase 3 Study Of JZP-110 Evaluating Excessive Sleepiness In Narcolepsy     11/29/2016
Flamel Technologies (FLML) Reaches Agreement With FDA On Protocol For Phase III Pivotal Trial Of FT218     10/7/2016
Theranexus Has Obtained An Orphan Drug Designation From The FDA For THN102 In The Treatment Of Narcolepsy     10/4/2016
Mylan (MYL) Launches First Generic of Nuvigil Tablets     6/1/2016
Theranexus: Preclinical Results Published In The Specialist Medical Journal Sleep     3/30/2016
Jazz Pharmaceuticals (JAZZ) Announces Second Quarter 2015 Financial Results     8/6/2015
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Clinical Development Program Evaluating JZP-110 As A Potential Treatment Of Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy Or With Obstructive Sleep Apnea (OSA)     6/8/2015
Jazz Pharmaceuticals (JAZZ) Announces First Patients Enrolled In Phase 3 Trial Of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy     12/3/2014
Jazz Pharmaceuticals plc (JAZZ) Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy     6/3/2014
Aerial BioPharma Announces Positive Results for ADX-N05 202; a Phase 2b Trial for Narcolepsy     10/1/2013
Aerial BioPharma Receives FDA Orphan Drug Designation for Narcolepsy Drug in Development     8/29/2012
UCB Group (UCBJF.PK) Release: European Medicines Agency Adopts Positive Opinion Recommending Approval Of Xyrem® For The Treatment Of Narcolepsy With Cataplexy In Adult Patients     1/25/2007
Jazz Pharmaceuticals, Inc. Release: Xyrem(R) (Sodium Oxybate) Now Available For The Treatment Of Excessive Daytime Sleepiness (EDS) In Patients With Narcolepsy     3/6/2006
Jazz Pharmaceuticals, Inc. Announces European Commission Marketing Approval Of Xyrem     12/9/2005

//-->